Arava and Hepatitis chronic active - a phase IV clinical study of FDA data

Summary:

Hepatitis chronic active is reported as a side effect among people who take Arava (leflunomide), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Celebrex, and have Juvenile rheumatoid arthritis.

The phase IV clinical study analyzes which people have Hepatitis chronic active when taking Arava. It is created by eHealthMe based on reports of 75,674 people who have side effects when taking Arava from the FDA, and is updated regularly.

What is Arava?

Arava has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 76,040 Arava users. Check the latest studies of Arava.

What is Hepatitis chronic active?

Hepatitis chronic active is found to be associated with 30 drugs and 91 conditions by eHealthMe. Check the latest studies of Hepatitis chronic active.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

75,674 people reported to have side effects when taking Arava.
Among them, 12 people (0.02%) have Hepatitis chronic active.

Could Arava cause Hepatitis chronic active?

Among these 12 people:

How long have people been on Arava when they have Hepatitis chronic active? *

What is the gender of people who have Hepatitis chronic active when taking Arava? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Hepatitis chronic active when taking Arava? *

What are other drugs people take besides Arava? *

What are other side effects people have besides Hepatitis chronic active? *

Fatty Liver: 4 people, 33.33%
Hepatic Fibrosis (scarring process that represents the liver's response to injury): 4 people, 33.33%
Hepatic Necrosis (large portions of liver die off due to severe liver disease): 4 people, 33.33%
Weakness: 4 people, 33.33%
White Blood Cell Count Increased: 2 people, 16.67%
Intervertebral Disc Herniation (spinal disc herniation): 2 people, 16.67%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 2 people, 16.67%
Hepatic Steatosis (fatty liver disease): 2 people, 16.67%
Hepatocellular Damage (liver damage): 2 people, 16.67%
Hepatitis Cholestatic (flow of bile from the liver is slowed or blocked): 2 people, 16.67%

What are the existing conditions these people have? *

Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 8.33%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Arava and have Hepatitis chronic active?

- Check whether Hepatitis chronic active is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arava:

Arava (76,040 reports)

Browse all side effects of Arava:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis chronic active:

Hepatitis chronic active (30 drugs)

Browse all the conditions that are associated with Hepatitis chronic active:

Hepatitis chronic active (91 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on leflunomide (the active ingredients of Arava) and Arava (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.